{"id":109333,"date":"2024-10-14T18:13:32","date_gmt":"2024-10-14T15:13:32","guid":{"rendered":"https:\/\/pozirk.online\/en\/news\/109333\/"},"modified":"2026-03-09T20:10:49","modified_gmt":"2026-03-09T20:10:49","slug":"bielfarmpram-expecting-13-percent-increase-drug-production-in-2024","status":"publish","type":"articles","link":"https:\/\/pozirk.online\/en\/news\/109333\/","title":{"rendered":"Bie\u0142farmpram expecting 13-percent increase in drug production in 2024"},"content":{"rendered":"\n

October 14, Pozirk<\/em>.<\/strong> The output of pharmaceutical products is expected to exceed 2 billion rubels ($611 million) in 2024, Ihar Mitrafana\u016d, CEO of the Bie\u0142farmpram conglomerate, said.<\/p>\n\n\n\n

He told reporters in Minsk that he is expecting an annual increase of 13.4 percent.<\/p>\n\n\n\n

Market capacity is projected at $1.17 billion. Over the last 10 years, it has grown by 10\u201314 percent annually, according to Mitrafana\u016d, from $1.01 billion in 2019 to $1.27 billion during the COVID-19 pandemic. Growth picked up after a decline in 2022 and 2023, he noted.<\/p>\n\n\n\n

He went on to say that Belarusian drug exports are expected to reach about $200 million by the end of the year. Belarusian companies sell drugs in 124 countries, but the Commonwealth of Independent States accounts for 90 percent of exports.<\/p>\n\n\n\n

In order to increase sales, managers are examining African and Asian markets and the possibility of express registration of Belarusian medicines there.<\/p>\n\n\n\n

\n\n
\n \"\"